http://www.regentherapeutics.com/regen

Consider a company with a market cap of around 10 million which could well in the future be generating revenue well in excess of that figure every year. Interested then read on and DYOR on Regen Therapeutics.

For some time now I have been a shareholder of RGT who have been working with a patented product Colostrinin as a treatment for Alzheimers. Tests so far would seem to indicate that it is a success and they are currently refining a pharmaceutical product.

Meantime they are also pushing forward on the nutraceutical front as tests have shown positive results in respect of mild cognitive disorders (memory loss etc). Further research is being carried out regarding other major illnesses. As at mid 2007 a launch is scheduled in the US for Q4 and there are rumours of an earlier launch in Australia possibly imminent based on the fact that adverts are already starting to appear see:- http://www.quantumevolution.com.au/oscommerce/index.php

They have also acquired a contract research organisation which should mean that research money for clinical trials that had previously been spent will now be kept inside the group.

February 2006 has seen Regen acquire the rights, following a feasibility study, in respect of other uses for a well known drug (Zolpidem) that has undergone phase 2 clinical trials where results are expected around August 2007. The new use relates to the positive effects that have been seen when treating stroke victims with the drug. There has been a lot of press interest which a web search should reveal.

An interview with the chairman (Percy Lomax) in the summer of 2004 talked of a nutraceutical product producing royalty payments of 10% on a possible 100 million sales per annum. The pharmaceutical version which also requires a licensing partner will if successful have projected sales of 1-5 billion again which would generate royalty payments to Regen. I leave you to contemplate just how high the share price would be if this were the case but suffice to say it will be many many times what it is now.

Acquisition (Oct 2004) of Guildford Clinical Pharmacology unit demonstrates not only that they are progressive and expanding but also thinking strategically for GCPUL being a research based company no doubt Regen can now keep such costs within the group whereas before testing had to be paid for elsewhere. This acquisition also means that they have revenue and are therefore no longer a "virtual" company.

A share issue in July 2007 means that they should now have funds in hand to take them through to cash generation. Hopefully this means we have seen the last of the issues excepting any used by way of acquiring profitable companies.

The North America link is an interesting one as perhaps in readiness for the launch of Colostrinin out there Regen set up an ADR programme which became effective in March 2005. ADR's ( American Depositary Receipts) are a way for US investors to buy shares in UK companies. In Regen's case one ADR is equivalent to 200 Regen UK shares so when an ADR is purhased the Bank of New York will buy the proportionate number of UK shares and convert them into ADR's for the investor. At present this is not a factor however with the launch of Colostrinin out there if successful it may mean that US investors will want to be involved in the company and that will have a direct positive impact on our share price. In the US Colostrum (from which Colostrinin is produced )is already a recognised and popular health product and so demand should be good.

So all in all exciting times ahead. There can be few shares around that offer the potential of this one although as always DYOR and good luck with your investments whatever you decide here.

imo, another of these mini-minoows that is best left alone, but if you are already invested, then plenty of room at the altar rail to ask for salvation!

i post a couple of charts for you, and it is not pretty ...... the 3 month chart is just to highlight the closeness of 25+50+200 dma, all of which are likely to pose resistance the 200 dma in particular ...... the longer term one (3 year) illustrates the steady decline to virtually an all time low

Media comment, click HERE

ReGen Therapeutics said the clinical study to explore the effects of zolpidem in people who have suffered brain damage confirmed that a novel formulation of zolpidem is non-sedating.

The company said the phase IIa study to explore the 'antidormancy' effect of zolpidem was conducted on twenty patients having various debilities as a consequence of brain damage.

A dose of 2.5 milligrams caused no more sedation than placebo, suggesting the possibility that repeated 2.5 mg spray doses will show efficacy without undue sedation, ReGen said. 'Based on these results we now have the confidence to continue the development of novel zolpidem formulations for the treatment of brain dormancy2,' chairman and chief executive Percy Lomax said.

Recent 'happenings' in ReGen:-

01 October 2007
ReGen's Cognitive Nutraceutical Colostrinin TM Launched in USA

ColostrininTM to be active ingredient in Metagenics' CogniSureTM, a product
being marketed as support for the maintenance of mental capacity

ReGen Therapeutics Plc (London) announced today that its licensee Metagenics,
Inc. has launched its cognitive nutraceutical, ColostrininTM, onto the US
market. Metagenics Inc. is a leading supplier of natural medicines to healthcare
professionals.

ColostrininTM is the active ingredient in Metagenics' healthy cognition support
formula, CogniSureTM. Initially CogniSureTM is being made available to consumers
via Metagenics' network of approximately 30,000 healthcare professionals across
the USA. These include physicians, chiropractors, acupuncturists, nutritionists,
and other healthcare professionals with a specific interest in nutritional
supplementation. The product is being made available as chocolate flavour
chewable tablets in blister packs containing 30 tablets. Further details of
availability are provided on Metagenics' website
www.metagenics.com

26 October 2007
Capital Consolidation


The Board believes that it is appropriate to prepare a reorganisation of the
Company's share capital involving the consolidation of the number of Existing
Ordinary Shares. The consolidation would reduce the total number of shares in
issue, simplify trading and settlement and also facilitate a more appropriate
trading price range for the shares. The Board believes that its presentations to
the US investment community over the last three and a half years have been well
received. Unfortunately, the current low level of the share price is a block on
US investment. The Company has an American Depository Receipt (ADR), which it
proposes to list on the OTCQX market in New York. This newly established trading
facility already includes a number of well-known European company stocks. The
Board considers that a higher underlying share price is necessary for this
listing to be a success.


It is proposed that every one hundred (100) Existing Ordinary Shares, currently
having a nominal value of 0.1p each, be consolidated into one New Ordinary Share
having a nominal value of 10p each.

29 October 2007

TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to
which voting rights are attached (ii):

ReGen Therapeutics Plc

2. Reason for the notification:

An acquisition or disposal of voting rights

3. Full name of person(s) subject to the notification obligation (iii):

Barclays PLC

4. Full name of shareholder(s) (if difference from 3):

Barclays Stockbrokers Ltd
Gerrard Investment Management Ltd

5. Date of the transaction and date on which the threshold is crossed or
reached (v):

25 October 2007

6. Date on which issued notified:

26 October 2007

7. Threshold(s) that is/are crossed or reached:

5% to 6%

8. Notified details

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code GB0004468319

Situation Previous to the triggering transaction (vi) -
Number of Shares 61,417,949
Number of Voting Rights (viii) 61,417,949

Resulting situation after the triggering transaction (viii) -
Number of Shares 61,980,949
Number of Voting Rights - Direct (x) N/A
Number of Voting Rights - Indirect (xi) 61,980,949
% of voting rights - Direct N/A
% of voting rights - Indirect 6.04

Perhaps we can now see a bit of positive movement in the SP. The BBC have a 45 min programme following 3 parents of coma victims to South Africa to see if Zolpidem could work for their daughters. The One Life documentary"The Waking Pill" will be shown on BBC One on Wednesday (October 31) at 10.40pm (times may vary by region).

ReGen Therapeutics said it has entered into a equity credit facility agreement of up to 2 mln stg with Duke Holdings Corp Ltd to provide a drawdown of capital in exchange for shares in the company.

The company said the initial facility of 2 mln stg is available in two tranches of 1 mln stg and that it has now issued a notice of an initial drawdown of up to 400,000 stg of shares, which may be split over a number of allotments to Duke.

ReGen also said has raised 204,648 stg before expenses by placing, directly and through its new broker Alexander David Securities Ltd, 629,685 shares at 32.5 pence each with existing investors. The company said it will use the funding to develop opportunities in the pharmaceutical sector 'in very uncertain financial market conditions.'

Executive Chairman Percy Lomax commented: 'As sales of CogniSure build up, ultimately the directors believe the company will become self financing; however the company is not yet at this point.'

Double figures gain today:

ReGen Therapeutics said it is sees market value of about $2.2 million in the first-half from the Colostrinin/CogniSure drug ordered by Metagenics Inc. based on the number of kilos ordered and assuming all are sold.